WO2020049429A1 - Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof - Google Patents
Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof Download PDFInfo
- Publication number
- WO2020049429A1 WO2020049429A1 PCT/IB2019/057324 IB2019057324W WO2020049429A1 WO 2020049429 A1 WO2020049429 A1 WO 2020049429A1 IB 2019057324 W IB2019057324 W IB 2019057324W WO 2020049429 A1 WO2020049429 A1 WO 2020049429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lapatinib
- pharmaceutical composition
- composition
- dosage form
- novel pharmaceutical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- 239000002136 L01XE07 - Lapatinib Substances 0.000 title claims abstract description 99
- 229960004891 lapatinib Drugs 0.000 title claims abstract description 96
- 239000008184 oral solid dosage form Substances 0.000 title claims abstract description 8
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 title claims description 99
- 238000004519 manufacturing process Methods 0.000 title description 14
- 239000003826 tablet Substances 0.000 claims abstract description 69
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 45
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 32
- 239000011230 binding agent Substances 0.000 claims abstract description 27
- -1 lapatinib ditosylate monohydrate Chemical class 0.000 claims abstract description 26
- 239000007884 disintegrant Substances 0.000 claims abstract description 23
- 239000000314 lubricant Substances 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 239000002552 dosage form Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000003085 diluting agent Substances 0.000 claims abstract description 11
- 229920003109 sodium starch glycolate Polymers 0.000 claims abstract description 11
- 239000008109 sodium starch glycolate Substances 0.000 claims abstract description 11
- 229940079832 sodium starch glycolate Drugs 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims description 57
- 239000011248 coating agent Substances 0.000 claims description 28
- 238000000576 coating method Methods 0.000 claims description 27
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 26
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 26
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 26
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 26
- 238000005461 lubrication Methods 0.000 claims description 22
- 238000007580 dry-mixing Methods 0.000 claims description 20
- 238000005469 granulation Methods 0.000 claims description 19
- 230000003179 granulation Effects 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 229930195725 Mannitol Natural products 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 16
- 229960001855 mannitol Drugs 0.000 claims description 16
- 235000010355 mannitol Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 235000002639 sodium chloride Nutrition 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 11
- 230000004584 weight gain Effects 0.000 claims description 11
- 235000019786 weight gain Nutrition 0.000 claims description 11
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 9
- 229960001021 lactose monohydrate Drugs 0.000 claims description 9
- 238000003801 milling Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 7
- 229960001375 lactose Drugs 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 4
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 3
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 3
- 229920000578 graft copolymer Polymers 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940096516 dextrates Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000829 kaolin Drugs 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 229960002160 maltose Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 229960000540 polacrilin potassium Drugs 0.000 claims description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 229960001320 lapatinib ditosylate Drugs 0.000 abstract description 22
- 238000004090 dissolution Methods 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 6
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 50
- 238000009472 formulation Methods 0.000 description 30
- 235000019359 magnesium stearate Nutrition 0.000 description 25
- 229920003081 Povidone K 30 Polymers 0.000 description 14
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229960003943 hypromellose Drugs 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940094060 tykerb Drugs 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000008185 minitablet Substances 0.000 description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OIQPTROHQCGFEF-QIKYXUGXSA-L Sunset Yellow FCF Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-QIKYXUGXSA-L 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010954 commercial manufacturing process Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007947 dispensing tablet Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- RLPIHWNHNYWVFO-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-ethylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)CC)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 RLPIHWNHNYWVFO-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 235000012751 sunset yellow FCF Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to novel oral solid dosage pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof, preferably in a tablet dosage form. Further, the present invention discloses the process for preparing the same. The present invention provides an economical and advanced dosage form over existing dosage form.
- Lapatinib is a small molecule of dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is orally active drug for breast cancer and used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
- EGFR epidermal growth factor receptor
- lapatinib ditosylate monohydrate is represented as below:
- Lapatinib is disclosed in US patent no. WO1999035146 and is marketed under the brand name of TYKERB ® (by Glaxo Smith Kline) which is of 250 mg, orange colored, oval shaped -biconvex, film-coated tablet for oral administration.
- TYKERB ® by Glaxo Smith Kline
- Each 250 mg tablet of TYKERB ® contains lapatinib ditosylate monohydrate or 250 mg lapatinib free base along with the inactive ingredients magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate and for coating of orange film-coat, FD&C yellow no. 6/sunset yellow FCF aluminum lake, hypromellose, macrogol/PEG 400, polysorbate 80 and titanium dioxide.
- the recommended dosage of TYKERB ® for advanced or metastatic breast cancer is 1250 mg (5 tablets) given orally once daily on days 1-21 continuously in combination with capecitabine 2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on days 1-14 in a repeating 21 -day cycle.
- PCT publication no. W02010023187 discloses a pharmaceutical composition with a high percentage of lapatinib as active pharmaceutical ingredient present in an amount of more than 60% by weight based on the total weight of the composition.
- W02014128107 exemplifies a pharmaceutical composition
- a pharmaceutical composition comprises lapatinib as an active ingredient along with one binder, one disintegrant, one lubricant, and one filler, wherein the filler comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the total weight of the pharmaceutical composition.
- WO 2010/023188 discloses pharmaceutical compositions comprising lapatinib or a pharmaceutically acceptable salt thereof wherein a unit dose of the composition contains 1200 to 1300 mg of the active pharmaceutical ingredient calculated as the free base.
- WO2007143483 reveals a method of treating cancer by administration of a combination of pyrimidine derivatives and quinazoline derivatives, more particularly combination of pazopanib and lapatinib for treatment of cancer.
- Indian patent application 970/MUM/2014 claims a pharmaceutical composition comprising lapatinib and one or more pharmaceutically acceptable excipients wherein the composition comprises nanosized lapatinib, having the particle size an average of less than about 2000 nm.
- Lapatinib formulations available currently in the market generally use microcrystalline cellulose and magnesium stearate as excipients.
- Microcrystalline cellulose is a widely used excipient and used in many pill and tablet formulations.
- the mannitol is inert excipient and is readily water soluble excipient.
- Cellulose derivatives when used as major component in the formulation have tendency to swell and result into higher variation when products are subjected to dissolution or pK studies. Being water soluble excipient, mannitol do not hinder the absorption of product and hence would be reduction in drug loss.
- Mannitol provides quite good compressibility as well and imparts adequate density to formulation, thereby making the formulation process more robust and advantageous and importantly scalability becomes quite smooth.
- mannitol has definitely advantage overusing cellulose derivatives.
- Cellulose derivatives in many cases are reported to have more variable processing parameters and pose challenges in commercial manufacturing process. The extent of use of such excipients becomes a limiting factor and hence excipients like mannitol enjoys better advantages.
- Sodium starch glycolate also like most other excipients and bulk additives is not healthy in high doses. Sodium starch glycolate was found to lengthen disintegration time when utilized at high concentrations. Further, it is found that depending on the source, it can cause adverse effects on certain individuals. People with allergy to com or with celiac disease may experience adverse effects.
- the present invention discloses a novel pharmaceutical composition of lapatinib that exclude the excipients like microcrystalline cellulose and sodium starch glycolate. Therefore, it is technically advanced and improved over existing prior arts.
- the primary object of the present invention is to provide a novel pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof for oral solid dosage form.
- Another object of the present invention is to provide the pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof for oral solid dosage form, preferably a tablet dosage form.
- Another object of the present invention is to provide an economical and advanced dosage form over existing dosage form and with less side effects.
- Yet another object of the present invention is to provide a pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof having excellent dissolution profile and higher stability with minimum use of excipients.
- Yet another object of the present invention is to provide a novel process for preparation of oral solid dosage pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof.
- Still another object of the present invention is to provide a pharmaceutical composition comprising lapatinib for the use in treatment of advanced or metastatic breast cancer.
- Another object of the present invention is to provide process for the preparation of pharmaceutical composition comprising lapatinib ditosylate and hydroxyl propyl methylcellulose (suitable for hot melt extrusion) and other suitable excipients, which then was encapsulated in hard gelatin capsule dosage form wherein faster dissolution of the lapatinib is obtained in recommended dissolution media.
- Another object of the present invention is to improve the solubility of lapatinib by complexation with cyclodextrin and its various modified derivatives.
- the inclusion complex obtained was mixed with other suitable excipients and encapsulated or compressed to form lapatinib tablets 250mg / 500mg tablet.
- the present invention discloses a novel pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof preferably oral solid dosage form of a tablet with pharmaceutically acceptable excipients and method of preparation thereof.
- the pharmaceutical composition of present invention comprises lapatinib ditosylate monohydrate with one or more pharmaceutically acceptable excipients selected from the group comprising of at least one diluent, at least one disintegrant, at least one binder, at least one lubricant, wherein the composition does not comprise microcrystalline cellulose and sodium starch glycolate.
- lapatinib ditosylate is in micro sized form have a particle size distribution Ds>o with ranging from 5 to 50 pm, preferably 5 to 20 pm and more preferably 5-15 pm and the particle size is tightly controlled that enhances the drug dissolution of the drug product.
- the pharmaceutical composition according to the present invention is economical and advanced dosage form over existing dosage form, with less side effects and time efficient, especially for large-scale production, whereby the pharmaceutical composition shows a desired dissolution profile and higher stability with minimum use of excipients.
- Figure 1 illustrates particle size distribution curve of micro sized particles of lapatinib ditosylate monohydrate of the present invention.
- the present invention discloses a novel pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof preferably oral solid dosage form of a tablet.
- the pharmaceutical composition of the present invention comprises lapatinib preferably ditosylate monohydrate with one or more pharmaceutically acceptable excipients selected from the group consisting of at least one diluent, at least one disintegrant, at least one binder, at least one lubricant, wherein the composition does not comprise microcrystalline cellulose and sodium starch glycolate.
- a novel pharmaceutical composition comprising lapatinib as an active ingredient and one or more pharmaceutically acceptable excipients including diluents/filler, disintegrants, binders, lubricants, but not limited thereof.
- lapatinib ditosylate monohydrate as an active ingredient along with pharmaceutically acceptable excipients selected from lactose, mannitol, Soluplus ® (polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol graft copolymer), povidone, croscarmellose sodium, magnesium stearate.
- pharmaceutically acceptable excipients selected from lactose, mannitol, Soluplus ® (polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol graft copolymer), povidone, croscarmellose sodium, magnesium stearate.
- General composition for 250 mg tablet of lapatinib of the present invention is as under:
- the pharmaceutical composition of the present invention comprises lapatinib as active ingredient in the dosage form in range from 25% to 50% w/w.
- Another embodiment of present invention discloses 500 mg tablet of lapatinib.
- General composition for 500 mg tablet of lapatinib of the present invention is as below:
- the novel pharmaceutical composition of lapatinib oral dosage form of comprises a lapatinib, more preferably lapatinib ditosylate monohydrate as an active ingredient along with pharmaceutically acceptable excipients selected from lactose, mannitol, Soluplus ® , Pharmaburst ® 500, dicalcium phosphate, Polyplasdone ® XL, povidone, Hypromellose, croscarmellose sodium, magnesium stearate.
- the present invention discloses an immediate-release formulation of lapatinib ditosylate monohydrate for oral dosage form.
- lapatinib having very less solubility in water
- the active ingredient used in the present invention is micronized and the particle size is tightly controlled that enhances the drug dissolution of the drug product.
- ditosylate salt is used which exhibited good compression characteristics.
- Inventors of the present invention provides a pharmaceutical composition of lapatinib which would be considered as patient compliant due its better dissolution profile which ultimately leads to enhanced bioavailability.
- lapatinib that comprises lapatinib, preferably ditosylate, more preferably in its monohydrate form with one or more pharmaceutically acceptable excipients selected from at least one diluent, at least one disintegrant, at least one binder, at least one lubricant; wherein diluent is preferably selected from lactose, mannitol, Soluplus ® ; binder is preferably selected from povidone, HPMC; disintegrant is preferably selected from croscarmellose sodium, Polyplasdone ® XL (crospovidone), and lubricant is preferably selected from magnesium stearate, sucrose stearate or sodium stearyl fumarate.
- the amount of lubricant magnesium stearate in the tablet of the present invention is adjusted to avoid sticking to the tableting tools. Further, the film coated tablet of the present invention facilitate swallowing and patient compliance.
- This composition of the present invention lacks excipients including microcrystalline cellulose and sodium starch glycolate that are present in innovator’s product.
- Microcrystalline cellulose is insoluble in water and avoidance of that has enhanced the solubility and bioavailability of the composition of the present invention. Therefore, solubility of the active ingredient is increased.
- the present invention resulted in achieving good dissolution profile with minimum use of excipients. Therefore, stability of solid dosage forms of the present invention is quite higher.
- diluents may be selected from the group consisting of dextrates, dextrin, dextrose, fructose, l-O-a-D-glucopyranosyl-D-mannitol, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactitol, lactose, lactose monohydrate, maltitol, mannitol, maltodextrin, maltose, Soluplus ® (polyvinyl caprolactam-polyvinyl acetate- polyethylene glycol graft copolymer), pregelatinized starch, sodium chloride, sorbitol, starches, sucrose, talc and xylitol or a mixture of one or more of said diluents.
- Disintegrants used for the preparation of solid oral dosage form are selected from the group consisting of carboxymethyl cellulose, low substituted hydroxypropyl cellulose, powdered cellulose, croscarmellose sodium, Polyplasdone ® XL (crospovidone), methylcellulose, polacrilin potassium, sodium alginate or a mixture of one or more of said disintegrants.
- Lubricants may be selected from the group consisting of calcium stearate, glyceryl palmitostearate, sodium benzoate, sodium stearyl fumarate, stearic acid, talc, zinc stearate and magnesium stearate or a mixture of one or more of said lubricants.
- the binders may be selected from the group consisting of hydroxyl propyl methyl cellulose (HPMC or hypromellose), polyvinyl pyrrolidone (povidone), hydroxyl propyl cellulose, polyvinyl alcohol, methyl cellulose, ethyl cellulose, gum arabic, alginic acid, polyethylene glycol (PEG), pregelatinized starch (PGS) and the like.
- HPMC hydroxyl propyl methyl cellulose
- povidone polyvinyl pyrrolidone
- hydroxyl propyl cellulose polyvinyl alcohol
- methyl cellulose methyl cellulose
- ethyl cellulose gum arabic
- alginic acid polyethylene glycol (PEG), pregelatinized starch (PGS) and the like.
- Glidants may be selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talc; preferably, the glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica.
- Solvents may be selected from the group consisting of short chain and long chain alcohols, acetone, and methylene dichloride (MDC).
- MDC methylene dichloride
- Coating mixture (Opadry ® ) or Tabcoat ® of present invention is consisting of hypomellose as film- forming agent, macrogol as plasticizer and polysorbate 80 as wetting agent. Further, titanium dioxide, yellow ferric oxide and red ferric oxide are used as colorants.
- the term“lapatinib” is not only limited to“lapatinib” per se but also includes in broader way its pharmaceutically acceptable derivatives thereof. These derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable isomers, pharmaceutically acceptable prodrugs, pharmaceutically acceptable enantiomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable esters, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
- lapatinib is present in the form of lapatinib ditosylate monohydrate in the present invention.
- active ingredient lapatinib have a particle size distribution Ds>o with ranging from 5 to 50 pm, preferably 5 to 15 pm.
- the present invention thus provides a pharmaceutical composition comprising lapatinib wherein the particle size of Lapatinib ditosylate is along with the unique formulation designed in such a way that lead to provide better dissolution profile and solubility of the drug.
- the particle size between range of 5 to 50 pm, preferably 5 to 15 pm gives better dissolution profile than highly reduced particle size.
- the pharmaceutical composition comprising lapatinib according to the present invention is administered orally through the solid dosage forms including tablets, capsules (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units), MUPS (multiple unit pellet systems), disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates, sachets (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates), powders for reconstitution and sprinkles, however, other dosage forms such as controlled release formulations, lyophilized formulations, modified release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, dual release formulations and the like.
- the pharmaceutical composition comprising lapatinib according to the present invention may be administered in a solid oral dosage form of a tablet including film coated tablet, sugar coated tablet, chewable tablet, delayed release tablet, , multiple compressed tablet, enteric coated tablets, effervescent tablet, dispensing tablet.
- the present invention also discloses a method of manufacturing the oral solid dosage pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof.
- Lapatinib API and other excipients are sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG) or any other suitable granulator. Then, dry mixing is done of the blend for 5 minutes.
- RMG rapid mixer granulator
- Binder is added to granulating fluid water under stirring. Stirring is continued till uniform solution is formed.
- dry mixture of the blend prepared in step (a) is blended in rapid mixer granulator (RMG) by adding binder solution prepared in stage (b) at an impeller speed of 80-100 RPM and chopper speed of 1000-2000 RPM.
- RMG rapid mixer granulator
- the wet granules prepared in step (c) are dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65°C till loss on drying (LOD) of the granules is less than 2%.
- FBP fluid bed processor
- Solvent is evaporated during the drying stage.
- Dried granules prepared in step (d) are sifted using 20# sieve, milling of the oversize granules are done using clit mill.
- Lubricant is added in the blend prepared in step (e) and lubrication is carried out for 3 minutes.
- Dry blend was granulated in rapid mixer granulator (RMG) by adding binder solution of povidone K30 at an impeller speed of 80-100 RPM and chopper speed of 1000-2000 RPM.
- Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
- the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
- FBP fluid bed processor
- Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
- RMG rapid mixer granulator
- the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%. 4) Then after, dried granules prepared were sifted using 20# sieve, milling of the oversize granules were done using clit mill.
- FBP fluid bed processor
- Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
- Lapatinib ditosylate monohydrate 405.00 mg Lactose monohydrate 349.70 mg Soluplus ® 37.30 mg
- Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
- the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
- FBP fluid bed processor
- Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
- Lapatinib ditosylate monohydrate 405.00 mg Lactose (Flowlac ® l00) 387.00 mg
- Lapatinib API, lactose (Flowlac ® 100) and Povidone K30 were sifted using appropriate size sieve and transferred to blender followed by mixing for 30 minutes. 2) Then, disintegrant Croscarmellose sodium added to above blend and blended for 10 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
- Lapatinib ditosylate monohydrate 405.00 mg Pharmaburst ® 500 387.00 mg Povidone K30 58.50 mg
- Lapatinib API, Pharmaburst ® 500 and povidone K30 were sifted using appropriate size sieve and transferred to blender and mixed for 30 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
- Lapatinib API, dicalcium phosphate were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
- RMG rapid mixer granulator
- the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
- FBP fluid bed processor
- Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight. 8) Then, coating of core tablets was carried out using coating mixture of Opadry ® till the weight gain on core tablet was 3%.
- RMG rapid mixer granulator
- the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
- FBP fluid bed processor
- Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
- Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
- the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
- FBP fluid bed processor
- Lubricated blend was compressed using suitable punch set at 1115 mg tablet weight.
- Dissolution rate is a critical property that need to study for final dosage form Comparative dissolution profile of the product of present invention with a reference product (tablet) was studied. Dissolution study of the pharmaceutical dosage of the present invention was carried out by HPLC.
- the dissolution method employed in the present invention is USP Apparatus II (paddle) with sinker at 55 RPM in 2% Tween 80 in 0.1 N HC1 for 45 min of time duration at (37 ⁇ 0.5) °C. Samples were taken at 10, 15, 30 and 45 minutes. The sample was filtered through a 0.45 pm syringe filter, transferred to HPLC vials and analyzed by HPLC. The following are the comparative dissolution data of the Lapatinib ditosylate monohydrate tablet of innovator reference product and final product of the present invention.
- composition in accordance with the present invention was subjected to stability study under stability analysis condition of 25°C ⁇ 2°C and relative humidity 60% ⁇ 5%. It was found to be adequately stable, as per general stability requirement under conditions. Moreover, the product is also stable in the similar manner in accelerated stability conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a novel pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof preferably oral solid dosage form of a tablet with pharmaceutically acceptable excipients and method of preparation thereof. The pharmaceutical composition of present invention comprises lapatinib ditosylate monohydrate with one or more pharmaceutically acceptable excipients selected from the group comprising of at least one diluent, at least one disintegrant, at least one binder, at least one lubricant, wherein the composition does not comprise microcrystalline cellulose and sodium starch glycolate. The pharmaceutical composition according to the present invention is economical and advanced dosage form over existing dosage form, with less side effects and time efficient, especially for large scale production, whereby the pharmaceutical composition shows a desired dissolution profile and higher stability with minimum use of excipients.
Description
NOVEL COMPOSITION OF LAPATINIB OF ORAL SOLID DOSAGE FORM AND METHOD OF MANUFACTURING THEREOF
FIELD OF THE INVENTION:
The present invention relates to novel oral solid dosage pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof, preferably in a tablet dosage form. Further, the present invention discloses the process for preparing the same. The present invention provides an economical and advanced dosage form over existing dosage form.
BACKGROUND OF THE INVENTION:
Lapatinib is a small molecule of dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is orally active drug for breast cancer and used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
It is present as the monohydrate of the ditosylate salt, with chemical name N-{3-chloro-4-[(3- fluorophenyl)methoxy]phenyl}-6-(5-{[(2-ethanesulfonylethyl) amino] methyl}furan-2- yl)quinazolin-4-amine and molecular formula C29H26CIFN4O4S (CTHxCESU H2O and a molecular weight of 943.5.
Structurally, lapatinib ditosylate monohydrate is represented as below:
LAPATINIB
Lapatinib is disclosed in US patent no. WO1999035146 and is marketed under the brand name of TYKERB® (by Glaxo Smith Kline) which is of 250 mg, orange colored, oval shaped -biconvex, film-coated tablet for oral administration. Each 250 mg tablet of TYKERB® contains lapatinib ditosylate monohydrate or 250 mg lapatinib free base along with the inactive ingredients magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate and for coating
of orange film-coat, FD&C yellow no. 6/sunset yellow FCF aluminum lake, hypromellose, macrogol/PEG 400, polysorbate 80 and titanium dioxide.
The recommended dosage of TYKERB® for advanced or metastatic breast cancer is 1250 mg (5 tablets) given orally once daily on days 1-21 continuously in combination with capecitabine 2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on days 1-14 in a repeating 21 -day cycle.
Breast cancer is the commonest form of cancer in women worldwide and second leading cause of cancer-related death in American women. Although treatment with chemotherapy, endocrine therapy and targeted therapy has significantly improved outcomes for women with early stage disease, overall survival for women with metastatic disease remains poor with a five-year survival rate of only 15% underscoring the need for novel therapeutic strategies.
PCT publication no. W02010023187 discloses a pharmaceutical composition with a high percentage of lapatinib as active pharmaceutical ingredient present in an amount of more than 60% by weight based on the total weight of the composition.
W02014128107 exemplifies a pharmaceutical composition comprises lapatinib as an active ingredient along with one binder, one disintegrant, one lubricant, and one filler, wherein the filler comprises microcrystalline cellulose in an amount of 10 to 30% by weight, relative to the total weight of the pharmaceutical composition.
WO 2010/023188 discloses pharmaceutical compositions comprising lapatinib or a pharmaceutically acceptable salt thereof wherein a unit dose of the composition contains 1200 to 1300 mg of the active pharmaceutical ingredient calculated as the free base.
WO2007143483 reveals a method of treating cancer by administration of a combination of pyrimidine derivatives and quinazoline derivatives, more particularly combination of pazopanib and lapatinib for treatment of cancer.
Indian patent application 970/MUM/2014 claims a pharmaceutical composition comprising lapatinib and one or more pharmaceutically acceptable excipients wherein the composition comprises nanosized lapatinib, having the particle size an average of less than about 2000 nm.
Lapatinib formulations available currently in the market generally use microcrystalline cellulose and magnesium stearate as excipients. Microcrystalline cellulose is a widely used excipient and used in many pill and tablet formulations. However, there are certain disadvantages and side effects there of the microcrystalline cellulose.
It should be noted that the mannitol is inert excipient and is readily water soluble excipient. Cellulose derivatives when used as major component in the formulation have tendency to swell and result into higher variation when products are subjected to dissolution or pK studies. Being water soluble excipient, mannitol do not hinder the absorption of product and hence would be reduction in drug loss. Mannitol provides quite good compressibility as well and imparts adequate density to formulation, thereby making the formulation process more robust and advantageous and importantly scalability becomes quite smooth. Hence mannitol has definitely advantage overusing cellulose derivatives. Cellulose derivatives in many cases are reported to have more variable processing parameters and pose challenges in commercial manufacturing process. The extent of use of such excipients becomes a limiting factor and hence excipients like mannitol enjoys better advantages.
Sodium starch glycolate also like most other excipients and bulk additives is not healthy in high doses. Sodium starch glycolate was found to lengthen disintegration time when utilized at high concentrations. Further, it is found that depending on the source, it can cause adverse effects on certain individuals. People with allergy to com or with celiac disease may experience adverse effects.
To overcome such instances, the present invention discloses a novel pharmaceutical composition of lapatinib that exclude the excipients like microcrystalline cellulose and sodium starch glycolate. Therefore, it is technically advanced and improved over existing prior arts.
OBJECT OF THE INVENTION
The primary object of the present invention is to provide a novel pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof for oral solid dosage form.
Another object of the present invention is to provide the pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof for oral solid dosage form, preferably a tablet dosage form.
Another object of the present invention is to provide an economical and advanced dosage form over existing dosage form and with less side effects.
Yet another object of the present invention is to provide a pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof without the use of microcrystalline cellulose and sodium starch glycolate.
Yet another object of the present invention is to provide a pharmaceutical composition of lapatinib active ingredient wherein lapatinib is in micro sized form have a particle size distribution Ds>o with ranging from 5 to 50 pm, preferably 5 to 20 pm and more preferably 5-15 pm.
Yet another object of the present invention is to provide a pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof having excellent dissolution profile and higher stability with minimum use of excipients.
Yet another object of the present invention is to provide a novel process for preparation of oral solid dosage pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof.
Still another object of the present invention is to provide a pharmaceutical composition comprising lapatinib for the use in treatment of advanced or metastatic breast cancer.
Another object of the present invention is to provide process for the preparation of pharmaceutical composition comprising lapatinib ditosylate and hydroxyl propyl methylcellulose (suitable for hot melt extrusion) and other suitable excipients, which then was encapsulated in hard gelatin capsule dosage form wherein faster dissolution of the lapatinib is obtained in recommended dissolution media.
Another object of the present invention is to improve the solubility of lapatinib by complexation with cyclodextrin and its various modified derivatives. The inclusion complex obtained was mixed with other suitable excipients and encapsulated or compressed to form lapatinib tablets 250mg / 500mg tablet.
SUMMARY OF THE INVENTION
The present invention discloses a novel pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof preferably oral solid dosage form of a tablet with pharmaceutically acceptable excipients and method of preparation thereof. The pharmaceutical composition of present invention comprises lapatinib ditosylate monohydrate with one or more pharmaceutically acceptable excipients selected from the group comprising of at least one diluent, at least one disintegrant, at least one binder, at least one lubricant, wherein the composition does not comprise microcrystalline cellulose and sodium starch glycolate. In the present invention, lapatinib ditosylate is in micro sized form have a particle size distribution Ds>o with ranging from 5 to 50 pm, preferably 5 to 20 pm and more preferably 5-15 pm and the particle size is tightly controlled that enhances the drug dissolution of the drug product.
The pharmaceutical composition according to the present invention is economical and advanced dosage form over existing dosage form, with less side effects and time efficient, especially for large-scale production, whereby the pharmaceutical composition shows a desired dissolution profile and higher stability with minimum use of excipients.
BRIEF DESCRIPTION OF THE DRAWINGS:
Figure 1: illustrates particle size distribution curve of micro sized particles of lapatinib ditosylate monohydrate of the present invention.
DETAILED DESCRIPTION OF THE INVENTION:
The nature of the invention is clearly described in the specification. The invention has various components and they are clearly described in the following pages of the complete specification. The present invention will now be disclosed by describing certain preferred and optional embodiments, to facilitate various aspects thereof.
The present invention discloses a novel pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof preferably oral solid dosage form of a tablet. The pharmaceutical composition of the present invention comprises lapatinib preferably ditosylate monohydrate with one or more pharmaceutically acceptable excipients selected from the group consisting of at least one diluent, at least one disintegrant, at least one binder, at least one lubricant, wherein the composition does not comprise microcrystalline cellulose and sodium starch glycolate.
In accordance with the present invention, a novel pharmaceutical composition comprising lapatinib as an active ingredient and one or more pharmaceutically acceptable excipients including diluents/filler, disintegrants, binders, lubricants, but not limited thereof.
In one preferred embodiment of the present invention comprises lapatinib ditosylate monohydrate as an active ingredient along with pharmaceutically acceptable excipients selected from lactose, mannitol, Soluplus® (polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol graft copolymer), povidone, croscarmellose sodium, magnesium stearate.
General composition for 250 mg tablet of lapatinib of the present invention is as under:
The pharmaceutical composition of the present invention comprises lapatinib as active ingredient in the dosage form in range from 25% to 50% w/w. Another embodiment of present invention discloses 500 mg tablet of lapatinib. General composition for 500 mg tablet of lapatinib of the present invention is as below:
The present invention discloses an immediate-release formulation of lapatinib ditosylate monohydrate for oral dosage form. As lapatinib having very less solubility in water, the active ingredient used in the present invention is micronized and the particle size is tightly controlled that enhances the drug dissolution of the drug product. Further, in the present invention, ditosylate salt is used which exhibited good compression characteristics.
Inventors of the present invention provides a pharmaceutical composition of lapatinib which would be considered as patient compliant due its better dissolution profile which ultimately leads to enhanced bioavailability.
Inventors of the present invention have developed the formulation of lapatinib that comprises lapatinib, preferably ditosylate, more preferably in its monohydrate form with one or more pharmaceutically acceptable excipients selected from at least one diluent, at least one disintegrant, at least one binder, at least one lubricant; wherein diluent is preferably selected from lactose, mannitol, Soluplus®; binder is preferably selected from povidone, HPMC; disintegrant is preferably selected from croscarmellose sodium, Polyplasdone® XL (crospovidone), and lubricant is preferably selected from magnesium stearate, sucrose stearate or sodium stearyl fumarate.
The amount of lubricant magnesium stearate in the tablet of the present invention is adjusted to avoid sticking to the tableting tools. Further, the film coated tablet of the present invention facilitate swallowing and patient compliance.
This composition of the present invention lacks excipients including microcrystalline cellulose and sodium starch glycolate that are present in innovator’s product. Microcrystalline cellulose is insoluble in water and avoidance of that has enhanced the solubility and bioavailability of the composition of the present invention. Therefore, solubility of the active ingredient is increased. The present invention resulted in achieving good dissolution profile with minimum use of excipients. Therefore, stability of solid dosage forms of the present invention is quite higher.
In further aspect of the present invention, diluents may be selected from the group consisting of dextrates, dextrin, dextrose, fructose, l-O-a-D-glucopyranosyl-D-mannitol, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactitol, lactose, lactose monohydrate,
maltitol, mannitol, maltodextrin, maltose, Soluplus® (polyvinyl caprolactam-polyvinyl acetate- polyethylene glycol graft copolymer), pregelatinized starch, sodium chloride, sorbitol, starches, sucrose, talc and xylitol or a mixture of one or more of said diluents.
Disintegrants used for the preparation of solid oral dosage form are selected from the group consisting of carboxymethyl cellulose, low substituted hydroxypropyl cellulose, powdered cellulose, croscarmellose sodium, Polyplasdone® XL (crospovidone), methylcellulose, polacrilin potassium, sodium alginate or a mixture of one or more of said disintegrants.
Lubricants may be selected from the group consisting of calcium stearate, glyceryl palmitostearate, sodium benzoate, sodium stearyl fumarate, stearic acid, talc, zinc stearate and magnesium stearate or a mixture of one or more of said lubricants.
The binders may be selected from the group consisting of hydroxyl propyl methyl cellulose (HPMC or hypromellose), polyvinyl pyrrolidone (povidone), hydroxyl propyl cellulose, polyvinyl alcohol, methyl cellulose, ethyl cellulose, gum arabic, alginic acid, polyethylene glycol (PEG), pregelatinized starch (PGS) and the like.
Glidants, if used, may be selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talc; preferably, the glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica.
Solvents may be selected from the group consisting of short chain and long chain alcohols, acetone, and methylene dichloride (MDC).
Coating mixture (Opadry®) or Tabcoat® of present invention is consisting of hypomellose as film- forming agent, macrogol as plasticizer and polysorbate 80 as wetting agent. Further, titanium dioxide, yellow ferric oxide and red ferric oxide are used as colorants.
The excipients used as listed above; however, it is not limited to the said excipients only.
In the present invention, the term“lapatinib” is not only limited to“lapatinib” per se but also includes in broader way its pharmaceutically acceptable derivatives thereof. These derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable isomers, pharmaceutically acceptable prodrugs, pharmaceutically acceptable enantiomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable esters, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc. Preferably, lapatinib is present in the form of lapatinib ditosylate monohydrate in the present invention.
In the present invention, active ingredient lapatinib have a particle size distribution Ds>o with ranging from 5 to 50 pm, preferably 5 to 15 pm.
The present invention thus provides a pharmaceutical composition comprising lapatinib wherein the particle size of Lapatinib ditosylate is along with the unique formulation designed in such a way that lead to provide better dissolution profile and solubility of the drug. As per the observation of inventor of the present invention that the particle size between range of 5 to 50 pm, preferably 5 to 15 pm gives better dissolution profile than highly reduced particle size.
In general scenario, it is reported that when particle size is highly reduced gives better dissolution profile of the drug. However, as per the inventors of the present invention contradicts with the above statement and observed that the composition of the present invention and moderately reduced particle size and not highly reduced particle size of the present product i.e. 5 to 50 pm are complimentary to each other in term to get better dissolution and purity profile under stability.
The pharmaceutical composition comprising lapatinib according to the present invention is administered orally through the solid dosage forms including tablets, capsules (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units), MUPS (multiple unit pellet systems), disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates, sachets (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, disintegrating tablets, dispersible tablets, granules, and microspheres, multiparticulates), powders for reconstitution and sprinkles, however, other dosage forms such as controlled release formulations, lyophilized formulations, modified release formulations, delayed release formulations, extended release formulations, pulsatile release formulations, dual release formulations and the like.
Preferably, the pharmaceutical composition comprising lapatinib according to the present invention may be administered in a solid oral dosage form of a tablet including film coated tablet, sugar coated tablet, chewable tablet, delayed release tablet, , multiple compressed tablet, enteric coated tablets, effervescent tablet, dispensing tablet.
Method of Manufacturing
The present invention also discloses a method of manufacturing the oral solid dosage pharmaceutical composition of lapatinib or a pharmaceutically acceptable salt thereof.
In the present process, a wet granulation process preferably with water as granulating agent is used.
The process of the present invention is divided in different following steps as below:
(a) Sifting and dry mixing
Lapatinib API and other excipients are sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG) or any other suitable granulator. Then, dry mixing is done of the blend for 5 minutes.
(b) Binder solution preparation
Binder is added to granulating fluid water under stirring. Stirring is continued till uniform solution is formed.
(c) Granulation
During the granulation stage, dry mixture of the blend prepared in step (a), is blended in rapid mixer granulator (RMG) by adding binder solution prepared in stage (b) at an impeller speed of 80-100 RPM and chopper speed of 1000-2000 RPM. Wet granules are kneaded for 30 seconds in rapid mixer granulator (RMG).
(d) Drying
After completing the granulation, the wet granules prepared in step (c) are dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65°C till loss on drying (LOD) of the granules is less than 2%.
Solvent is evaporated during the drying stage.
(e) Sifting and Blending
Dried granules prepared in step (d) are sifted using 20# sieve, milling of the oversize granules are done using clit mill.
Then, sifted and milled dried granules are blended along with disintegrant and blended for 10 minutes.
(f) Lubrication
Lubricant is added in the blend prepared in step (e) and lubrication is carried out for 3 minutes.
(g) Compression
Above prepared lubricated blend is compressed using suitable punch set at 900 mg tablet weight.
(h) Coating
Then, coating of core tablets is carried out using suitable coating mixture (Opadry®) until the weight gain on core tablet is 3%.
The present invention can be described by way of example or strategy only. It is to be recognized that modifications falling within the scope and spirit of the description or claims, which would be obvious to a person skilled in the art based upon the disclosure herein, are also considered to be included within the scope of this disclosure.
EXAMPLES:
Example: 1 Lapatinib formulation preparation 1
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg Lactose monohydrate 387.00 mg
Binder solution
Povidone K30 58.50 mg Purified water Q.S.
Blending
Croscarmellose sodium 40.50 mg
Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg
Manufacturing process for Lapatinib composition (Example: 1)
1) Lapatinib API and lactose monohydrate were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
2) Dry blend was granulated in rapid mixer granulator (RMG) by adding binder solution of povidone K30 at an impeller speed of 80-100 RPM and chopper speed of 1000-2000 RPM. Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
3) After completing the granulation, the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
4) Then after, dried granules prepared were sifted using 20# sieve, milling of the oversize granules were done using clit mill.
5) Then, sifted and milled dried granules were blended along with disintegrant croscarmellose sodium and blended for 10 minutes.
6) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
7) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
8) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
Example: 2 Lapatinib formulation preparation 2
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg
Mannitol 387.00 mg
Binder solution
Povidone K30 58.50 mg
Purified water Q.S.
Blending
Croscarmellose sodium 40.50 mg Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg
Manufacturing process for Lapatinib formulation (Example: 2)
1) Lapatinib API and mannitol were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
2) Then, granulation was done of dry blend in rapid mixer granulator (RMG) by adding binder solution of povidone K30 at an impeller speed of 80-100 RPM and chopper speed of 1000- 2000 RPM. Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
3) After completing the granulation, the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
4) Then after, dried granules prepared were sifted using 20# sieve, milling of the oversize granules were done using clit mill.
5) Then, sifted and milled dried granules were blended along with disintegrant croscarmellose sodium and blended for 10 minutes.
6) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
7) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
8) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
Example: 3 Lapatinib formulation preparation 3
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg Lactose monohydrate 349.70 mg Soluplus® 37.30 mg
Binder solution
Povidone K30 58.50 mg Purified water Q.S.
Blending
Croscarmellose sodium 40.50 mg Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg
Manufacturing process for Lapatinib formulation (Example: 3)
1) Lapatinib API, lactose monohydrate and Soluplus® were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
2) Then, granulation was done of dry blend in rapid mixer granulator (RMG) by adding binder solution of povidone K30 at an impeller speed of 80-100 RPM and chopper speed of 1000- 2000 RPM. Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
3) After completing the granulation, the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
4) Then after, dried granules prepared were sifted using 20# sieve, milling of the oversize granules were done using clit mill.
5) Then, sifted and milled dried granules were blended along with disintegrant croscarmellose sodium and blended for 10 minutes.
6) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
7) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
8) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
Example: 4 Lapatinib formulation preparation 4
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg
Mannitol 349.70 mg
Soluplus® 37.30 mg
Binder solution
Povidone K30 58.50 mg Purified water Q.S.
Blending
Croscarmellose sodium 40.50 mg Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg Manufacturing process for Lapatinib formulation (Example: 4)
1) Lapatinib API, mannitol and Soluplus® were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
2) Then, granulation was done of dry blend in rapid mixer granulator (RMG) by adding binder solution of povidone K30 at an impeller speed of 80-100 RPM and chopper speed of 1000- 2000 RPM. Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
3) After completing the granulation, the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
4) Then after, dried granules prepared were sifted using 20# sieve, milling of the oversize granules were done using clit mill.
5) Then, sifted and milled dried granules were blended along with disintegrant croscarmellose sodium and blended for 10 minutes.
6) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
7) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
8) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
Example: 5 Lapatinib formulation preparation 5
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg Lactose (Flowlac®l00) 387.00 mg
Povidone K30 58.50 mg
Blending
Croscarmellose sodium
40.50 mg
Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg
Manufacturing process for Lapatinib formulation (Example: 5)
1) Lapatinib API, lactose (Flowlac® 100) and Povidone K30 were sifted using appropriate size sieve and transferred to blender followed by mixing for 30 minutes.
2) Then, disintegrant Croscarmellose sodium added to above blend and blended for 10 minutes.
3) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
4) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
5) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
Example: 6 Lapatinib formulation preparation 6
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg Pharmaburst®500 387.00 mg Povidone K30 58.50 mg
Blending
Croscarmellose sodium
40.50 mg
Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg
Manufacturing process for Lapatinib formulation (Example: 6)
1) Lapatinib API, Pharmaburst®500 and povidone K30 were sifted using appropriate size sieve and transferred to blender and mixed for 30 minutes.
2) Then, disintegrant Croscarmellose sodium added to above blend and blended for 10 minutes.
3) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
4) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
5) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
Example: 7 Lapatinib formulation preparation 7
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg
Dicalcium phosphate 387.00 mg
Binder solution
Povidone K30 58.50 mg
Purified water Q.S.
Blending
Croscarmellose sodium
40.50 mg
Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg
Manufacturing process for Lapatinib formulation (Example: 7)
1) Lapatinib API, dicalcium phosphate were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
2) Then, granulation was done of dry blend in rapid mixer granulator (RMG) by adding binder solution of povidone K30 at an impeller speed of 80-100 RPM and chopper speed of 1000- 2000 RPM. Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
3) After completing the granulation, the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
4) Then after, dried granules prepared were sifted using 20# sieve, milling of the oversize granules were done using clit mill.
5) Then, sifted and milled dried granules were blended along with disintegrant croscarmellose sodium and blended for 10 minutes.
6) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
7) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
8) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
Example: 8 Lapatinib formulation preparation 8
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 405.00 mg Lactose monohydrate 423.00 mg HPMC 22.50 mg
Granulation
Purified water Q.S.
Blending
Croscarmellose sodium 40.50 mg
Lubrication
Magnesium stearate 9.00 mg
Total Weight 900.00 mg Manufacturing process for Lapatinib formulation (Example: 8)
1) Lapatinib API, lactose monohydrate and HPMC were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
2) Then, granulation was done of dry blend in rapid mixer granulator (RMG) by adding purified water at an impeller speed of 80-100 RPM and chopper speed of 1000-2000 RPM. Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
3) After completing the granulation, the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
4) Then after, dried granules prepared were using, milling of the oversize granules were done using clit mill.
5) Then, sifted and milled dried granules were blended along with disintegrant croscarmellose sodium and blended for 10 minutes.
6) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
7) Lubricated blend was compressed using suitable punch set at 900 mg tablet weight.
8) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%. Example: 9 Lapatinib formulation preparation 9
Ingredients Quantity per Tablet
Dry mixing
Lapatinib ditosylate monohydrate 810.00 mg Mannitol 208.12 mg
Croscarmellose sodium 50.00 mg
Binder solution
Hypromellose E5 27.88 mg Purified water Q.S.
Blending
Croscarmellose sodium 10.00 mg
Lubrication
Magnesium stearate 9.00 mg
Total Weight 1115.00 mg
Manufacturing process for Lapatinib formulation (Example: 9)
1) Lapatinib API, mannitol and croscarmellose sodium were sifted using appropriate size sieve and transferred to rapid mixer granulator (RMG). Then, dry mixing was done of the blend for 5 minutes.
2) Then, granulation was done of dry blend in rapid mixer granulator (RMG) by adding binder solution of Hypromellose E5 at an impeller speed of 80-100 RPM and chopper speed of 1000-2000 RPM. Wet granules prepared were kneaded for 30 seconds in rapid mixer granulator (RMG).
3) After completing the granulation, the wet granules prepared were dried in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2%.
4) Then after, dried granules prepared were sifted using 20# sieve, milling of the oversize granules were done using clit mill.
5) Then, sifted and milled dried granules were blended along with disintegrant croscarmellose sodium and blended for 10 minutes.
6) Lubricant magnesium stearate was added in the blend prepared in step (5) and lubrication was carried out for 3 minutes.
7) Lubricated blend was compressed using suitable punch set at 1115 mg tablet weight.
8) Then, coating of core tablets was carried out using coating mixture of Opadry® till the weight gain on core tablet was 3%.
DISSOLUTION STUDY
Dissolution rate is a critical property that need to study for final dosage form Comparative dissolution profile of the product of present invention with a reference product (tablet) was studied. Dissolution study of the pharmaceutical dosage of the present invention was carried out by HPLC.
The dissolution method employed in the present invention is USP Apparatus II (paddle) with sinker at 55 RPM in 2% Tween 80 in 0.1 N HC1 for 45 min of time duration at (37 ± 0.5) °C. Samples were taken at 10, 15, 30 and 45 minutes. The sample was filtered through a 0.45 pm syringe filter, transferred to HPLC vials and analyzed by HPLC. The following are the comparative dissolution data of the Lapatinib ditosylate monohydrate tablet of innovator reference product and final product of the present invention.
Table: 10 Comparative dissolution study of Lapatinib tablet of present invention with
Innovator product
Surprisingly it was found from the above data provided in table 10 that the lapatinib tablets of the present invention underwent rapid and complete dissolution initially compare to innovator product and even after 1 month when tested using the USP Apparatus (II) in comparison with the reference product of the innovator. As increase in the solubility and dissolution rates leads to improvement in the bioavailability of the drug with consistency and uniformity.
STABILITY STUDY
The composition in accordance with the present invention was subjected to stability study under stability analysis condition of 25°C±2°C and relative humidity 60%±5%. It was found to be adequately stable, as per general stability requirement under conditions. Moreover, the product is also stable in the similar manner in accelerated stability conditions.
Table: 11 Stability study of Lapatinib tablet of present invention and its comparison with
Innovator reference product
*ND = Not detected
As indicated in above table, the result of the stability study indicates that lapatinib composition in accordance with the present invention exhibits excellent storage stability.
The invention described herein comprises in various objects as mentioned above and their description in relation to characteristics, compositions and process adopted. While these aspects are emphasised in the invention, any variations of the invention described above are not to be regarded as departure from the spirit and scope of the invention as described.
Claims
1. A novel pharmaceutical composition of lapatinib of oral solid dosage form comprising lapatinib or pharmaceutically acceptable salt or polymorph thereof and one or more pharmaceutically acceptable excipients selected from diluents/fillers, disintegrants, binders, lubricants, coating agent, but not limited thereof, wherein the composition lacks excipients including microcrystalline cellulose and sodium starch glycolate.
2. The novel pharmaceutical composition of lapatinib as claimed in claim 1, wherein the composition comprising:
3. The novel pharmaceutical composition of lapatinib as claimed in claim 1, wherein the composition comprising:
4. The novel pharmaceutical composition of lapatinib as claimed in claims 1-3, wherein the composition is in solid dosage form preferably selected from tablet, capsule, MUPS (multiple unit pellet system), powder, granules, sachets, pellets, powders for reconstitution and sprinkles.
5. The novel pharmaceutical composition of lapatinib as claimed in claims 1-4, wherein the composition is in solid dosage form preferably a tablet dosage form.
6. The novel pharmaceutical composition of lapatinib as claimed in claims 1 to 5, wherein the content of lapatinib in the dosage form is in range from 25% w/w to 80% w/w.
7. The novel pharmaceutical composition of lapatinib as claimed in claims 1-6, wherein the dosage strength of the composition is 250 mg and 500 mg tablets.
8. The novel pharmaceutical composition of lapatinib as claimed in claims 1-7, wherein lapatinib is in particle size Ds>o ranging from 5 to 50 pm.
9. The novel pharmaceutical composition of lapatinib as claimed in claims 1-8, wherein pharmaceutically acceptable diluent/filler is selected from lactose, lactose monohydrate, mannitol, sorbitol, sucrose; dextrates, dextrin, dextrose, fructose, Soluplus® (polyvinyl caprolactam -polyvinyl acetate-polyethylene glycol graft copolymer), dicalcium phosphate, 1- O-a-D-glucopyranosyl-D-mannitol, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactitol, maltitol, maltodextrin, maltose, pregelatinized starch, sodium chloride, sorbitol, starches, sucrose, talc and xylitol or a mixture of one or more of said diluents, preferably lactose monohydrate, wherein microcrystalline cellulose is not used in the composition.
10. The novel pharmaceutical composition of lapatinib as claimed in claims 1-8, wherein pharmaceutically acceptable disintegrant is selected from carboxymethyl cellulose, low substituted hydroxypropyl cellulose, powdered cellulose, croscarmellose sodium, Polyplasdone® XL (crospovidone), methylcellulose, polacrilin potassium, sodium alginate or a mixture of one or more of said disintegrants, preferably croscarmellose sodium, wherein sodium starch glycolate is not used in the composition.
11. A process for preparation of a novel pharmaceutical composition of lapatinib comprising the following steps:
(a) Sifting and dry mixing
sifting of lapatinib and other excipients using appropriate size sieve and transferring to rapid mixer granulator (RMG) or any other suitable granulator; dry mixing of the blend for 5 minutes;
(b) Binder solution preparation
adding binder to granulating fluid water under stirring continuously till uniform solution formed;
(c) Granulation
blending of dry mixture of the blend prepared in step (a) in rapid mixer granulator (RMG) by adding binder solution prepared in stage (b) at an impeller speed 80-100 RPM and chopper speed of 1000-2000 RPM;
kneading of wet granules for 30 seconds in rapid mixer granulator (RMG);
(d) Drying
after completing the granulation process, drying of the wet granules prepared in step (c) in the fluid bed processor (FBP) at inlet air temperature 45 to 65 °C till loss on drying (LOD) of the granules is less than 2% and evaporating the solvent for drying;
(e) Sifting and Blending
sifting of dried granules prepared in step (d) using 20# sieve, milling of the oversize granules using clit mill;
blending of sifted and milled dried granules along with disintegrant and blending for 10 minutes;
(f) Lubrication
adding lubricant in the blend prepared in step (e) and carrying out lubrication for 3 minutes;
(g) Compression
compressing the lubricated blend prepared in step (f) using suitable punch set tablet weight;
(h) Coating
coating of core tablets using suitable coating mixture till the weight gain on core tablet of up to 3%.
12. The process for preparation of a novel pharmaceutical composition of lapatinib as claimed in claim 11, wherein coating mixture is of Opadry® or Tabcoat®.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19857473.3A EP3846787A4 (en) | 2018-09-03 | 2019-08-30 | NEW COMPOSITION OF LAPATINIB IN SOLID ORAL GALENIC FORM AND METHOD OF MANUFACTURING |
| BR112021004047-1A BR112021004047A2 (en) | 2018-09-03 | 2019-08-30 | new pharmaceutical composition of lapatinib and process for preparing a new pharmaceutical composition of lapatinib |
| MX2021002441A MX2021002441A (en) | 2018-09-03 | 2019-08-30 | Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof. |
| PH12021550451A PH12021550451A1 (en) | 2018-09-03 | 2021-03-02 | Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof |
| ZA2021/01538A ZA202101538B (en) | 2018-09-03 | 2021-03-05 | Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821032977 | 2018-09-03 | ||
| IN201821032977 | 2018-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020049429A1 true WO2020049429A1 (en) | 2020-03-12 |
Family
ID=69723001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2019/057324 WO2020049429A1 (en) | 2018-09-03 | 2019-08-30 | Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3846787A4 (en) |
| BR (1) | BR112021004047A2 (en) |
| CL (1) | CL2021000512A1 (en) |
| MX (1) | MX2021002441A (en) |
| PH (1) | PH12021550451A1 (en) |
| WO (1) | WO2020049429A1 (en) |
| ZA (1) | ZA202101538B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012017448A2 (en) * | 2010-08-03 | 2012-02-09 | Hetero Research Foundation | Salts of lapatinib |
| WO2015145145A1 (en) * | 2014-03-24 | 2015-10-01 | Cipla Limited | Pharmaceutical composition comprising lapatinib |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2158913A1 (en) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| EP2158912A1 (en) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| JP2013526578A (en) * | 2010-05-21 | 2013-06-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | combination |
| CN106511289A (en) * | 2015-09-10 | 2017-03-22 | 湖北生物医药产业技术研究院有限公司 | Benzenesulfonicacid lapatinib tablets and preparing method thereof |
-
2019
- 2019-08-30 MX MX2021002441A patent/MX2021002441A/en unknown
- 2019-08-30 EP EP19857473.3A patent/EP3846787A4/en active Pending
- 2019-08-30 WO PCT/IB2019/057324 patent/WO2020049429A1/en unknown
- 2019-08-30 BR BR112021004047-1A patent/BR112021004047A2/en unknown
-
2021
- 2021-03-01 CL CL2021000512A patent/CL2021000512A1/en unknown
- 2021-03-02 PH PH12021550451A patent/PH12021550451A1/en unknown
- 2021-03-05 ZA ZA2021/01538A patent/ZA202101538B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012017448A2 (en) * | 2010-08-03 | 2012-02-09 | Hetero Research Foundation | Salts of lapatinib |
| WO2015145145A1 (en) * | 2014-03-24 | 2015-10-01 | Cipla Limited | Pharmaceutical composition comprising lapatinib |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP3846787A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021550451A1 (en) | 2021-09-27 |
| EP3846787A1 (en) | 2021-07-14 |
| ZA202101538B (en) | 2022-07-27 |
| BR112021004047A2 (en) | 2021-05-25 |
| CL2021000512A1 (en) | 2021-11-26 |
| MX2021002441A (en) | 2021-03-25 |
| EP3846787A4 (en) | 2022-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5419866B2 (en) | New pharmaceutical composition | |
| AU2019203327A1 (en) | Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder | |
| WO2013082706A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
| CA3104695A1 (en) | Formulations of ag10 | |
| WO2006123213A1 (en) | Modified release formulations of gliclazide | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| WO2008122994A2 (en) | Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof | |
| US20100035846A1 (en) | Method for the treatment of acne and certain dosage forms thereof | |
| EP4058025A1 (en) | Pharmaceutical compositions comprising ticagrelor | |
| WO2016046797A1 (en) | Pharmaceutical composition having improved content uniformity | |
| WO2020049429A1 (en) | Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof | |
| RU2821950C2 (en) | New composition of lapatinib as a solid dosage form for oral use and a method of its manufacture | |
| WO2019008426A1 (en) | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof | |
| WO2012107090A1 (en) | Granulated composition comprising tadalafil and a disintegrant | |
| JP2020090484A (en) | Medicine tablet comprising erlotinib as active principle | |
| JP2020176090A (en) | Method for Producing Solid Formulation Containing Dasatinib Anhydride | |
| CA3098208A1 (en) | Tablet compositions comprising abiraterone acetate | |
| AU2018454263B2 (en) | Dosage form containing abiraterone acetate | |
| US20250144100A1 (en) | Pharmaceutical composition comprising ibrutinib | |
| EP3761965A1 (en) | Ticagrelor-containing tablet formulation | |
| RU2723255C2 (en) | Extrudate with sodium mycophenolate to produce peroral solid dosage form | |
| CA3187241A1 (en) | Pharmaceutical compositions comprising ribociclib | |
| CN115381788A (en) | Tofacitinib citrate preparation and preparation method thereof | |
| JP2024531701A (en) | Bempedoic acid pharmaceutical composition | |
| WO2023227997A1 (en) | Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19857473 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021004047 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 2019857473 Country of ref document: EP Effective date: 20210406 |
|
| ENP | Entry into the national phase |
Ref document number: 112021004047 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210303 |